Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of QL2108 vs Dupixent in Moderate-to-Severe Atopic Dermatitis
NCT06884891Phase 3
Key facts
- Status
- Not yet recruiting
- Start
- Apr 2025
- Primary completion
- May 2027
- Sponsor
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies
- Drugs
- QL2108
- Conditions
- atopic dermatitis (AD)
01
Overview
Phase 3, randomised, double-blind trial of QL2108 in atopic dermatitis (AD), sponsored by Qilu Pharmaceutical. Primary endpoint: Proportion of patients achieving EASI-75 at 16 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults with moderate-to-severe atopic dermatitis with a disease history of >= 1 year and inadequate response to topical treatments (implied by moderate-severe criteria).
04
Endpoints
Primary
Proportion of patients achieving EASI-75
Secondary
Proportion of patients achieving EASI-75
Proportion of patients achieving IGA-TS
Beyond the preview
Go deeper on NCT06884891.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884891.